What is FDA Project Optimus and How Will it Impact Oncology Drug Development?
47:22
Smarter Clinical Document Automation for Transparency and Disclosure Requirements
54:26
What Oncology Drug Developers Should Expect from the FDA’s Project Optimus
55:19
How to Define & Measure Clinical Endpoints to Optimize Your Oncology Drug Dosing
25:32
Axiom Crossroads: Go-To-Market Strategies
1:28:43
Modeling and Simulation to Select Oncology Dosages - Session 1
54:15
PBPK modeling of Distinct Change in OATP1B Substrate Pharmacokinetics during OATP1B-Mediated DDIs
1:05:36
Project Optimus – FDA’s New Dose Optimization & Selection Paradigm in Oncology Drug Development
42:12